rAd5

BIOLOGICAL2 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), HIV Vaccine Trials Network

Conditions

HIV Infections

Phase 1

Safety and Immune Response to Preventive HIV Immunization With Adenovirus Serotype 5 or 35 Vector

CompletedNCT00801697

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Start: 2009-02-28End: 2015-04-30Updated: 2021-10-14

Safety of and Immune Response to Prime/Boost Vaccine Regimens in Healthy, HIV-1 Uninfected, Ad5 Seronegative Adults

CompletedNCT00961883

HIV Vaccine Trials NetworkHIV Infections

Start: 2009-08-31Updated: 2013-09-06

Related Papers

Sequence and vector shapes vaccine induced antibody effector functions in HIV vaccine trials

PLoS Pathogens2021-11-292 citations

HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial

Journal of Clinical Investigation2014-10-0130 citations

A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults.

2012-08-0369 citations